The Scalpel's Edge

Dr. Tim Sayed looks at breast implant removal, breast implant illness, and the challenge of restoring breast volume after explant surgery, especially for women who have little natural breast tissue or not enough body fat for traditional fat transfer. He explains why removing an implant does not simply return the breast to its pre-augmentation appearance and why concerns about shape and volume can become an important part of the exp...

Dr. Tim Sayed continues his conversation about retatrutide, the investigational GLP-1 medication drawing widespread attention for weight loss, by looking beyond the clinical results and focusing on the growing black market surrounding the drug. He examines how people are obtaining products advertised through encrypted messaging platforms, overseas suppliers, and online marketplaces despite retatrutide not being FDA approved or lega...

Dr. Tim Sayed explores retatrutide, the investigational GLP-1 medication generating significant attention for medically supervised weight loss, and explains why its early clinical trial results have created so much excitement. He walks through the Phase 3 obesity data released by Eli Lilly, comparing reported weight loss outcomes with existing GLP-1 medications while explaining how retatrutide's triple agonist mechanism differs fro...

Dr. Tim Sayed walks through a recently accepted study from the Journal of Clinical Oncology Practice showing that GLP-1 medications like Ozempic, Mounjaro, and Zepbound are associated with a significant reduction in breast cancer incidence in overweight women. The paper, led by researchers at the University of Pennsylvania, analyzed electronic health records from roughly 111,000 women ages 45 to 80 with a BMI over 25, comparing bre...

Dr. Tim Sayed walks through a recent New York Times article on food noise — the persistent mental chatter about eating that many people with obesity describe as relentless — and what GLP-1 medications like semaglutide and tirzepatide appear to do to quiet it. Drawing on both his clinical experience prescribing these medications and his own personal use of them, Sayed unpacks the concept of the set point: the weight a bo...

Dr. Tim Sayed walks through an April 2026 study published in Nature that analyzed over 410,000 Reddit posts from people using semaglutide and tirzepatide, using AI language models to extract and categorize what patients were actually saying about their experiences on these medications. The study identified roughly 67,000 self-reporting users, and among them, 43.5% described at least one side effect, with nausea leading at 37%, foll...

Dr. Tim Sayed speaks with Rachel Blogg, a licensed psychotherapist and athlete who spent roughly three and a half years navigating breast augmentation, multiple revisions, capsular contracture, implant malposition, and eventually explant surgery before finding relief from symptoms she hadn't initially connected to her implants at all. Rachel's account moves through the full arc — from her original decision to augment after br...

Dr. Tim Sayed opens with a published personal account from a 56-year-old runner and author who had saline implants placed in the early 2000s and chose, two decades later, to have them removed and stay flat. The story moves through familiar territory for explant patients — the original decision made from insecurity, the body changes that followed breastfeeding, the capsular contracture that eventually developed, and the years ...

Dr. Tim Sayed takes a closer look at the latest shift in medically supervised weight loss with the FDA approval of an oral GLP-1 medication. After years of injections dominating the space, a once daily pill introduces a new layer of accessibility, convenience, and patient choice.

He walks through how these medications actually work in the body, from slowing gastric emptying to quieting food noise, and why they’ve been so impac...

Dr. Tim Sayed takes a thoughtful look at newly published data from the Achieve 3 trial, a 52-week head-to-head study comparing Eli Lilly’s investigational oral GLP-1, orforglipron, to oral semaglutide in adults with type 2 diabetes not adequately controlled on metformin.

Published in The Lancet, the study showed greater A1C reduction and more weight loss at higher doses of orforglipron, with improvements appearing as early as ...

On The Scalpel’s Edge, Dr. Tim Sayed takes a clear-eyed look at where GLP-1 weight loss medications are headed and why the landscape feels so unsettled right now.

From the FDA’s latest move against compounded GLP-1 drugs to the rise of direct-to-consumer platforms and the new TrumpRX pricing model, this is an honest, surgeon-level reflection on access, affordability, and control. Dr. Sayed shares how these shifts affect ...

Dr. Tim Sayed walks through some recent developments in the GLP-1 space that raise a question almost everyone on these medications eventually asks. What happens when you stop. He reflects on new data around weight regain after discontinuing GLP-1 drugs, including a large meta-analysis showing how quickly weight and metabolic markers tend to return toward baseline once the medication is stopped.

He also breaks down early clinical dat...

On The Scalpel’s Edge, Dr. Tim Sayed talks with Elizabeth Everett about her experience with breast implant illness and what it was like to spend years feeling dismissed while her body kept sending louder and louder signals. She shares why she chose implants after having her third son, how symptoms slowly built over time, and the way stress, hormones, and a foreign body in her system seemed to create a perfect storm.

Elizabeth ...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes a deep dive into the latest research on GLP1 medications and the lesser known side effects patients may experience. Drawing from new studies, clinical insights, and his own experience with GLP1 therapy, Dr. Sayed breaks down how these medications may influence anemia risk, micronutrient deficiencies, appetite changes, and overall metabolic health.

He also explores new ...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes listeners inside the world of personalized genetic testing and how it can transform perioperative planning for explant patients and anyone seeking deeper insight into their inflammatory health.

Dr. Sayed breaks down the SHARP program’s integrated approach, which combines genomic testing, supplements, psychological support, and lifestyle guidance to help patients ...

Explore the growing movement of breast implant removal as Dr. Tim Sayed breaks down why twenty four well known celebrities decided to explant. In this powerful episode of The Scalpel’s Edge, Dr. Sayed explains the emotional, physical, and aesthetic reasons behind their decisions and highlights the rising awareness around breast implant illness, autoimmune symptoms, and personal identity. He also shares insights from his doubl...

A new era of weight management is on the horizon. In this episode of The Scalpel’s Edge, learn how oral GLP-1 medications like semaglutide (Rebelsus) are changing the landscape of obesity care and cardiovascular health. Explore key findings from the OASIS-4 Phase 3 trial, new FDA updates, and what the data reveals about blood sugar control, heart health, and weight reduction across all age groups. Discover why oral options ma...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed reviews a newly published study from Colombia examining outcomes in women with breast implant illness following explant surgery. With over 125 patients and 18 months of follow-up, this research reveals significant improvements in symptoms such as joint pain, fatigue, and hair loss — and offers valuable insight into the science, skepticism, and evolving understanding o...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed breaks down a recent CNN feature on the growing movement around explant surgery and breast implant illness. From celebrity testimonials like Alyssa Milano’s to the troubling stories of patients who felt pressured by surgeons, Dr. Sayed dives deep into what’s driving the rise in breast implant removals. He explores the science, the stigma, and the shifting mindse...